More

Categories

Countries

Itacitinib

TypeName: Business Offer
Category:
Offer Date:2019/09/04
Country: United States
Summary: Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Now it is in a Phase III trial for the treatment of graft-versus-host disease. https://www.bocsci.com/itacitinib-cas-1334298-90-6-item-474483.html
Description:
OfferId: 5440
Name:Alex Brown
Telphone:
Email:[email protected]

Advertising

Danny Auto Glass
Dwell Christian Therapy & Training
Handyman Pros of Oceanside
Matt The Driveway Guy, LLC
Oxford Minibus & Coaches
PPC Locksmith
Virgin Islands Retreats
Categories
No Man flag